Related Experiment Video

Updated: Mar 27, 2026

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

18.5K

Methodology of clinical trials in lung cancer

Jessica Menis1, Benjamin Besse2, Denis Lacombe1

  • 1EORTC Headquarters, Brussels, Belgium.

Chinese Clinical Oncology
|January 6, 2016
PubMed

Insights

New cancer targets require personalized medicine and innovative clinical trials. Integrating bioinformatics and health economics is key for tailored cancer care across Europe.

Area of Science:

  • Oncology
  • Translational Medicine
  • Health Services Research

Background:

  • Advancements in cancer biology reveal novel therapeutic targets, necessitating a shift from traditional cancer diagnosis and treatment strategies.
  • The conventional 'one size fits all' model is insufficient due to significant patient-to-patient variability in treatment response.

Purpose of the Study:

  • To highlight the need for innovative clinical trial designs that incorporate patient-specific data.
  • To emphasize the integration of multidisciplinary knowledge, including bioinformatics, biostatistics, epidemiology, and health economics, for personalized cancer care.
  • To discuss the emerging initiatives aimed at harmonizing healthcare landscapes across Europe for improved cancer treatment.

Main Methods:

  • Review of current trends in cancer target identification and drug development.
  • Analysis of the limitations of classical treatment approaches.
  • Exploration of the role of interdisciplinary collaboration in modern oncology research.
  • Examination of European initiatives for healthcare harmonization.

Main Results:

  • Identification of new cancer targets is transforming drug development towards personalized medicine.
  • Tailored treatment approaches are essential to account for individual patient variations.
  • Innovative trial designs integrating diverse scientific disciplines are crucial for advancing cancer care.
  • Pan-European collaborations are emerging to create a unified healthcare landscape.

Conclusions:

  • The evolving landscape of cancer biology demands a paradigm shift towards precision medicine.
  • Multidisciplinary approaches and innovative trial designs are critical for effective, personalized cancer treatment.
  • Harmonization efforts in Europe aim to standardize and improve cancer care delivery across the region.
Keywords:
Clinical trialdesignlung cancer

More Related Videos

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.9K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

11.1K

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
11.1K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.4K
Statistical Methods for Analyzing Epidemiological Data01:25

Statistical Methods for Analyzing Epidemiological Data

Epidemiological data primarily involves information on specific populations' occurrence, distribution, and determinants of health and diseases. This data is crucial for understanding disease patterns and impacts, aiding public health decision-making and disease prevention strategies. The analysis of epidemiological data employs various statistical methods to interpret health-related data effectively. Here are some commonly used methods:
1.2K
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
698
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
823